SCHEMBL27032575

SCHEMBL27032575

CC(Br)C(=O)c1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.53
BAD Q92934 1/20 0.53
PTPN1 P18031 2/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
NPC1 O15118 3/20 0.40
PDPK1 O15530 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1938267 0.94 CES2 (0.50) BCL2L1BADPTPN1CES2CES1
SCHEMBL4457061 0.84 HPGD (0.46) CES2CES1ALDH1A1CYP1A2HTT
SCHEMBL1928398 0.82 SMN1; SMN2 (0.57) PTPN1ALDH1A1CYP1A2CYP2C9NPC1
SCHEMBL11689860 0.81 BCL2L1 (0.53) BCL2L1BADPTPN1CES2CES1
SCHEMBL204960 0.77 CES2 (0.54) BCL2L1BADPTPN1CES2CES1
SCHEMBL6726501 0.77 CES2 (0.54) BCL2L1BADPTPN1CES2CES1
SCHEMBL3364624 0.77 GSK3B (0.61) BCL2L1BADPTPN1CES2CES1
SCHEMBL4102288 0.77 ALDH1A1 (0.51) PTPN1CES2CES1ALDH1A1CYP1A2
SCHEMBL7948329 0.76 CES2 (0.43) BCL2L1BADPTPN1CES2CES1
SCHEMBL2448326 0.75 CES2 (0.52) BCL2L1BADPTPN1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030875-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-07-09 US disclosed
EP-3846793-B1 EIF4E INHIBITORS AND USES THEREOF PIC THERAPEUTICS INC (US) 2024-01-24 EP disclosed
US-20220089587-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2022-03-24 US disclosed
CN-113164419-A EIF4E inhibitors and uses thereof 皮克医疗公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030875-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 BCL2L1 2634/4885BAD 2232/4885PTPN1 2316/4885
US-20220089587-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EEF2K BCL2L1 2778/4885BAD 2453/4885PTPN1 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.